Vitamin D and cancer: An overview on epidemiological studies

Advances in Experimental Medicine and Biology

Volumn 810, Issue , 2014, Pages 17-32

  Mena, José Manuel Ordóñez ^a   Brenner, Hermann ^a  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

1,25 DIHYDROXYERGOCALCIFEROL; CHOLESTANETRIOL 26 MONOOXYGENASE; VITAMIN D; VITAMIN D RECEPTOR; 1,25-DIHYDROXYVITAMIN D; 25 HYDROXYVITAMIN D; 25-HYDROXYVITAMIN D; CALCITRIOL; CALCITRIOL RECEPTOR; DRUG DERIVATIVE;

ALCOHOL CONSUMPTION; BREAST CANCER; CANCER INCIDENCE; CANCER MORTALITY; CANCER RISK; CANCER SURVIVAL; CELL DIFFERENTIATION; CELL PROLIFERATION; COLORECTAL CANCER; DISEASE ASSOCIATION; ESOPHAGUS CANCER; GENE LINKAGE DISEQUILIBRIUM; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC TRANSCRIPTION; GENETIC VARIABILITY; HUMAN; LIQUID CHROMATOGRAPHY; LIVER CANCER; LUNG CANCER; MALIGNANT NEOPLASM; PANCREAS CANCER; PRIORITY JOURNAL; PROSTATE CANCER; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SINGLE NUCLEOTIDE POLYMORPHISM; STOMACH CANCER; TANDEM MASS SPECTROMETRY; VITAMIN INTAKE; VITAMIN METABOLISM; BLOOD; BREAST TUMOR; COLORECTAL TUMOR; EPIDEMIOLOGY; FEMALE; GENE EXPRESSION; GENETICS; MALE; METABOLISM; PATHOLOGY; PROSTATE TUMOR; REVIEW; RISK;

BREAST NEOPLASMS; COLORECTAL NEOPLASMS; EPIDEMIOLOGIC STUDIES; FEMALE; GENE EXPRESSION; HUMANS; MALE; POLYMORPHISM, GENETIC; PROSTATIC NEOPLASMS; RECEPTORS, CALCITRIOL; RISK; VITAMIN D;

EID: 84907160119     PISSN: 00652598     EISSN: 22148019     Source Type: Book Series    
DOI: None     Document Type: Chapter

References (83)

1. Garland CF, Garland FC. Do sunlight and vitamin D reduce the likelihood of colon cancer? Int J Epidemiol 1980; 9:227-31; PMID:7440046; http://dx.doi.org/10.1093/ije/9.3.227.
2. Grant WB. Ecological studies of the UVB-vitamin D-cancer hypothesis. Anticancer Res 2012; 32:223-36; PMID:22213311.
3. Chiang KC, Yeh CN, Chen MF, Chen TC. Hepatocellular carcinoma and vitamin D: a review. J Gastroenterol Hepatol 2011; 26: 1597-603; PMID:21880026; http://dx.doi.org/10.1111/j.l440-1746.2011.06892.x.
4. Khadilkar VV, Khadilkar AV. Use of Vitamin Din Various Disorders. [Epub ahead of print]. Indian J Pediatr 2012; PMID:22956345; http://dx.doi.org/10.1007/s12098-012-0877-7.
5. Fleet JC, De Smet M, Johnson R, Li Y. Vitamin D and cancer: a review of molecular mechanisms. Biochem J 2012; 441:61-76; PMID:22168439; http://dx.doi.org/10.1042/BJ20110744.
6. Giovannucci E, Liu Y, Rimm EB, Hollis BW, Fuchs CS, Stampfer MJ, et al. Prospective study of predictors of vitamin D status and cancer incidence and mortality in men. J Natl Cancer Inst 2006; 98:451-9; PMID: 16595781; http://dx.doi.org/10.1093/jnci/dij101.
7. Giovannucci E, Liu Y, Willett WC. Cancer incidence and mortality and vitamin Din black and white male health professionals. Cancer Epidemiol Biomarkers Prev 2006; 15:2467-72; PMID: 17132768; http://dx.doi.org/10.1158/1055-9965.EPI-06-0357.
8. Michaëlsson K, Baron JA, Snellman G, Gedeborg R, Byberg L, Sundström J, et al. Plasma vitamin D and mortality in older men: a community-based prospective cohort study. Am J Clin Nutr 2010; 92:841-8; PMID:20720256; http://dx.doi.org/10.3945/ajcn.20 10.29749.
9. de Boer IH, Levin G, Robinson-Cohen C, Biggs ML, Hoofuagle AN, Siscovick DS, et al. Serum25-hydroxyvitamin D concentration and risk for major clinical disease events in a community-based population of older adults: a cohort study. Ann Intern Med 2012; 156:627-34; PMID:22547472.
10. Pilz S, Dobnig H, Winklhofer-Roob B, Riedm Uller G, Fischer JE, Seelhorst U, et al. Low serum levels of 25-hydroxyvitamin D predict fatal cancer in patients referred to coronary angiography. Cancer Epidemiol Biomarkers Prev 2008; 17:1228-33; PMID: 18463400; http://dx.doi.org/10.1158/1055-9965.EPI-08-0002.
11. Hutchinson MS, Grirnnes G, Joakimsen RM, Figenschau Y, Jorde R. Low serum 25-hydroxyvitamin D levels are associated with increased all-cause mortality risk in a general population: the Tromsø study. Eur J Endocrinol 2010; 162:935-42; PMID:20 185562; http://dx.doi.org/10.1530/EJE-09-1041.
12. Semba RD, Houston DK, Bandinelli S, Sun K, Cherubini A, Cappola AR, etal. Relationship of 25-hydroxyvitamin D with all-cause and cardiovascular disease mortality in older community-dwelling adults. Eur J Clin Nutr 2010; 64:203-9; PMID: 19953106; http://dx.doi.org/10.1038/ejcn.2009.140.
13. Melamed ML, Michos ED, Post W, Astor B. 25-hydroxyvitamin D levels and the risk of mortality in the general population. Arch Intern Med 2008; 168:1629-37; PMID:l8695076; http://dx.doi.org/10.1001/archinte.168.15.1629.
14. Freedman DM, Looker AC, Ahnet CC, Linet MS, Graubard BI. Serum 25-hydroxyvitamin D and cancer mortality in the NHANES III study (1988-2006). Cancer Res 2010; 70:8587-97; PMID:20847342; http://dx.doi.org/10.1158/0008-5472.CAN-10-1420.
15. Cawthon PM, Parimi N, Barrett-Connor E, Laughlin GA, Ensrud KE, Hoffinan AR, et al. Osteoporotic Fractures in Men (Mr OS) Research Group. Serum 25-hydroxyvitamin D, parathyroid hormone, and mortality in older men. JClin Endocrinol Metab 2010;95:4625-34;PMID:20631024; http://dx.doi.org/10.1210/jc.2010-0638.
16. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. GLOBOCAN 2008 v2.0, Cancer Incidence and Mortality Worldwide: IARC Cancer Base No. 10 [Internet]. Lyon, France: International Agency for Research on Cancer; 2010. Available from: http://globocan.iarc.fr, accessed on 10/10/2012.
17. Gandini S, Boniol M, Haukka J, Byrnes G, Cox B, Sneyd MJ, et al. Meta-analysis of observational studies of serum 25-hydroxyvitamin D levels and colorectal, breast and prostate cancer and colorectal adenoma Int J Cancer 2011; 128:1414-24; PMID:20473927; http://dx.doi.org/10.1002/ijc.25439.
18. Yin L, Grandi N, Raum E, Haug U, Arndt V, Brenner H. Meta-analysis: longitudinal studies of serum vitamin D and colorectal cancer risk. Aliment Pharmacol Ther 2009; 30:113-25; PMID: 19392870; http://dx.doi.org/10.1111/j.1365-2036.2009.04022.x.
19. Ma Y, Zhang P, Wang F, Yang J, Liu Z, Qin H. Association between vitamin D and risk of colorectal cancer: a systematic review of prospective studies. J Clin Oncol 20 11;29:3775-82; PMID:21876081; http://dx.doi.org/10.1200/JC0.2011.35.7566.
20. Touvier M, Chan DS, Lau R, Aune D, Vieira R, Greenwood DC, et al. Meta-analyses of vitamin D intake, 25-hydroxyvitamin D status, vitamin Dreceptorpolymorphisms, andcolorectal cancer risk. Cancer Epidemiol Biomarkers Prev 2011; 20:1003-16; PMID:21378269; http://dx.doi.org/10.1158/1055-9965. EPI-10-1141.
21. Lee JE, Li H, Chan AT, Hollis BW, Lee IM, Stampfer MJ, et al. Circulating levels of vitamin D and colon and rectal cancer: the Physicians' Health Study and a meta-analysis of prospective studies. Cancer Prev Res (Phila) 2011; 4:735-43; PMID:21430073; http://dx.doi.org/10.1158/1940-6207.CAPR-10-0289.
22. Fedirko V, Riboli E, Tjønneland A, Ferrari P, Olsen A, Bueno-de-Mesquita HB, et al. Prediagnostic 25-hydroxyvitamin D, VDR and CASR polymorphisms, and survival in patients with colorectal cancer in western European ppulations. Cancer Epidemiol Biomarkers Prev 2012; 21:582-93; PMID:22278364; http://dx.doi.org/10.1158/1055-9965.EPI-11-1065.
23. Bai YH, Lu H, Hong D, Lin CC, Yu Z, Chen BC. Vitamin D receptor gene polymorphisms and colorectal cancer risk: a systematic meta-analysis. World J Gastroenterol 2012; 18:1672-9; PMID:22529698; http://dx.doi.org/10.3748/wjg.v18.i14.1672.
24. Köstner K, Denzer N, Miiller CS, Klein R, Tilgen W, Reichrath J. The relevance of vitamin D receptor (VDR) gene polymorphisms for cancer: are view of the literature. Anticancer Res 2009; 29:3511-36;PMID: 19667145.
25. Gilbert R, Martin RM, Beynon R, Harris R, Savovic J, Zuccolo L, et al. Associations of circulating and dietary vitamin D with prostate cancer risk: a systematic review and dose-response meta-analysis. Cancer Causes Control 2011; 22:319-40; PMID:21203822; http://dx.doi.org/10.1007Is10552-010-9706-3.
26. Yin L, Raurn E, Haug U, Arndt V, Brenner H. Meta-analysis of longitudinal studies: Serum vitamin D and prostate cancer risk. Cancer Epidemiol 2009; 33:435-45; PMID: 19939760; http://dx.doi.org/10.1016/j. canep.2009.10.014.
27. Brändstedt J, Almquist M, Manjer J, Maim J. Vitamin D, PTH, and calcium and the risk of prostate cancer: a prospective nested case-control study. Cancer Causes Control 2012; 23: 1377-85; PMID:22706676; http://dx.doi.org/10.1007Is10552-012-9948-3.
28. Gilbert R, Metcalfe C, Fraser WD, Donovan J, Hamdy F, Neal DE, et al. Associations of circulating 25-hydroxyvitamin D with prostate cancer diagnosis, stage and grade. Int J Cancer 2012; 131:1187-96; PMID:22033893; http://dx.doi.org/10.1002/ijc.27327.
29. Gilbert R, Metcalfe C, Fraser WD, Donovan J, Hamdy F, Neal DE, et al. Associations of circulating retinol, vitamin E, and I,25-dihydroxyvitamin D with prostate cancer diagnosis, stage, and grade. Cancer Causes Control 2012; 23: 1865-73; PMID:22926301; http://dx.doi.org/10.1007/s10552-012-0052-5.
30. Berndt SI, Dodson JL, Huang WY, Nicodemus KK. A systematic review of vitamin D receptor gene polymorphisms and prostate cancer risk. J Urol 2006; 175:1613-23; PMID:l6600714; http://dx.doi.org/10.1016/S0022-5347(05)00958-4.
31. Shuii M, Mucci LA, Kraft P, Tamimi RM, Lindstrom S, Penney KL, et al. Vitamin D-relatedgeneticvariation, plasma vitamin D, and risk of lethal prostate cancer: a prospective nested case-control study. J Natl Cancer Inst 2012; 104:690-9; PMID:22499501; http://dx.doi.org/10.1093/jnci/djsl89.
32. Chen P, Hu P, Xie D, Qin Y, Wang F, Wang H. Meta-analysis of vitamin D, calcium and the prevention of breast cancer. Breast Cancer Res Treat 2010; 121:469-77; PMID: 19851861; http:l/dx.doi.org/10.1007/s10549-009-0593-9.
33. Yin L, Grandi N, Raum E, Haug U, Arndt V, Brenner H. Meta-analysis: serum vitamin D and breast cancer risk. Eur J Cancer 2010; 46:2196-205; PMID:20456946; http://dx.doi.org/10.1016/j.ejca2010.03.037.
34. Tang C, Chen N, Wu M, Yuan H, Du Y. Fokl polymorphismofvitamin Dreceptorgene contributes to breast cancer susceptibility: a meta-analysis. Breast Cancer Res Treat 2009; 117:391-9; PMID: 19145484; http://dx.doi.org/10.1007Is10549-008-0262-4.
35. Dorjgochoo T, Delahanty R, Lu W, Long J, Cai Q, Zheng Y, et al. Common genetic variants in the vitamin D pathway including genome-wide associated variants are not associated with breast cancer risk among Chinese women. Cancer Epidemiol Biomarkers Prev 2011; 20:2313-6; PMID:21828234; http://dx.doi.org/10.1158/1055-9965.EPI-ll-0704.
36. Herr C, Greulich T, Koczulla RA, Meyer S, Zakharkina T, Branscheidt M, et al. The role of vitamin Din pulmonary disease: COPD, asthma, infection, and cancer. Respir Res 2011; 12:31;PMID:21418564; http://dx.doi.org/10.1186/1465-9921-12-31.
37. Coussens LM, Werb Z. Inflammation and cancer. Nature 2002; 420:860-7; PMID: 12490959; http://dx.doi.org/10.1038/nature01322.
38. Mohr SB, Garland CF, Gorham ED, Grant WB, Garland FC. Could ultraviolet B irradiance and vitamin D be associated with lower incidence rates of lung cancer? J Epidemiol Community Health 2008; 62:69-74; PMID: 18079336; http://dx.doi.org/10.1136/jech.2006.052571.
39. Zhou W, Suk R, Liu G, Park S, Neuberg DS, Wain JC, et al. Vitamin Dis associated with improved survival in early-stage non-small cell lung cancer patients. Cancer Epidemiol Biomarkers Prev 2005; 14:2303-9; PMID: 16214909; http://dx.doi.org/10.1158/1055-9965.EPI-05-0335.
40. Zhou W, Heist RS, Liu G, Asomaning K, Neuberg DS, Hollis BW, et al. Circulating 25-hydroxyvitamin D levels predict survival in early-stage non-small-cell lung cancer patients. J Clin Oncol 2007; 25:479-85; PMID: 17290055; http://dx.doi.org/10.1200/JC0.2006.07.5358.
41. Freedman DM, Looker AC, Chang SC, Graubard BI. Prospective study of serum vitamin D and cancer mortality in the United States. J Natl Cancer Inst 2007; 99:1594-602; PMID:l7971526; http://dx.doi. org/10.1093/jnci/djm204.
42. Kilkkinen A, Knekt P, Helillvaara M, Rissanen H, Mamiemi J, Hakulinen T, et al. Vitamin D status and the risk of lung cancer: a cohort study in Finland. Cancer Epidemiol Biomarkers Prev 2008; 17:3274-8; PMID: 18990771; http://dx.doi.org/10.1158/1055-996S.EPI-08-0199.
43. Weinstein SJ, Yu K, Horst RL, Parisi D, Virtamo J, AIbanes D. Serum 25-hydroxyvitamin D and risk oflung cancer in male smokers: a nested case-control study. PLo S One 2011; 6:e20796; PMID:21695165; http://dx.doi.org/10.1371/joumal.pone.0020796.
44. Cheng TY, Neuhouser ML. Serum 25-hydroxyvitamin D, vitamin A, and lung cancer mortality in the US population: a potential nutrient-nutrient interaction. Cancer Causes Control 2012; 23: 1557-65; PMID:22829430; http://dx.doi.org/10.1007Is10552-012-0033-8.
45. Kim SH, Chen G, King AN, Jeon CK, Christensen PJ, Zhao L, et al. Characterization of vitamin D receptor (VDR)inlungadenocarcinoma. Lung Cancer 2012;77:265-71;PMID:22564539; http://dx.doi.org/10.1016/j.lungcan.2012.04.010.
46. Ranmath N, Kim S, Christensen PJ. Vitamin D and lung cancer. Expert Rev Respir Med 2011; 5:305-9; PMID:21702651; http://dx.doi.org/10.1586/ers.ll.31.
47. Dogan I, Onen HI, Yurdakul AS, Konac E, Ozturk C, Varol A, et al. Polymorphisms in the vitamin D receptor gene and risk of lung cancer. Med Sci Monit 2009; 15:BR232-42; PMID: 19644412.
48. Heist RS, Zhou W, Wang Z, Liu G, Neuberg D, Su L, et al. Circulating 25-hydroxyvitamin D, VDR polymorphisms, and survival in advanced non-small-cell lung cancer. J Clin Oncol 2008; 26:5596-602; PMID: 18936471; http://dx.doi.org/10.1200/JC0.2008.18.0406.
49. Li L, Ying XJ, Sun TT, Yi K, Tian HL, Sun R, et al. Overview of methodological quality of systematic reviews about gastric cancer risk and protective factors. Asian Pac J Cancer Prev 2012; 13:2069-79;PMID:2290 1173; http://dx.doi.org/10.7314/APJCP.2012.13.5.2069.
50. La Vecchia C, Ferraroni M, D'Avanzo B, Decarli A, Franceschi S. Selected micronutrient intake and the risk of gastric cancer. Cancer Epidemiol Biomarkers Prev 1994; 3:393-8; PMID:7920206.
51. Chen W, Dawsey SM, Qiao YL, Mark SD, Dong ZW, Taylor PR, et al. Prospective study of serum 2S(OH)-vitamin D concentration and risk of oesophageal and gastric cancers. Br J Cancer 2007; 97:123-8; PMID: 17551495; http://dx.doi.org/10.1038/sj.bjc.6603834.
52. Gallicchio L, Helzlsouer KJ, Chow WH, Freedman DM, Hankinson SE, Hartge P, et al. Circulating 25-hydroxyvitamin D and the risk of rarer cancers: Design and methods of the Cohort Consortium Vitamin D Pooling Project of Rarer Cancers. Am J Epidemiol 2010; 172:10-20; PMID:20562188; http://dx.doi.org/10.1093/ajelkwq116.
53. Abnet CC, Chen Y, Chow WH, Gao YT, Helzlsouer KJ, Le Marchand L, et al. Circulating 25-hydroxyvitamin D and risk of esophageal and gastric cancer: Cohort Consortium Vitamin D Pooling Projectof Rarer Cancers. Am J Epidemiol 2010; 172:94-106; PMID:20562192; http://dx.doi.org/10.1093/aje/kwq121.
54. Ren C, Qiu MZ, Wang DS, Luo HY, Zhang DS, Wang ZQ, et al. Prognostic effects of25-hydroxyvitamin D levels in gastric cancer. JTransl Med 2012; 10:16; PMID:22284859; http://dx.doi.org/10.1186/1479-5876-10-16.
55. Abnet CC, Chen W, Dawsey SM, Wei WQ, Roth MJ, Liu B, et al. Serum 2S(OH)-vitamin D concentration and risk of esophageal squamous dysplasia. Cancer Epidemiol Biomarkers Prev 2007; 16:1889-93; PMID: 17855710; http://dx.doi.org/10.1158/1OSS-996S.EPI-07-0461.
56. Skinner HG, Michaud DS, Giovannucci E, Willett WC, Colditz GA, Fuchs CS. Vitamin D intake and the risk for pancreatic cancer in two cohort studies. Cancer Epidemiol Biomarkers Prev 2006; 15:1688-95; PMID: 16985031; http://dx.doi.org/10.1158/1OSS-996S.EPI-06-0206.
57. Zablotska LB, Gong Z, Wang F, Holly EA, Bracci PM. Vitamin D, calcium, and retinol intake, and pancreatic cancer in a population-based case-control study in the San Francisco Bay area. Cancer Causes Control 2011; 22:91-100; PMID:21072578; http://dx.doi.org/10.1007/s10552-010-9678-3.
58. Bao Y, Ng K, Wolpin BM, Michaud DS, Giovannucci E, Fuchs CS. Predicted vitamin D status and pancreatic cancer risk in two prospective cohort studies. Br J Cancer 2010; 102:1422-7;PMID:20389298; http://dx.doi.org/10.1038/sj.bjc.6605658.
59. Stolzenberg-Solomon RZ, Vieth R, Azad A, Pietinen P, Taylor PR, Virtamo J, et al. A prospective nested case­ control study of vitamin D status and pancreatic cancer risk in male smokers. Cancer Res 2006; 66:10213-9; PMID: 17047087; http://dx.doi.org/10.1158/0008-5472.CAN-06-1876.
60. Stolzenberg-Solomon RZ, Jacobs EJ, Arslan AA, Qi D, Patel AV, Helzlsouer KJ, et al. Circulating 25-hydroxyvitamin D and risk of pancreatic cancer: Cohort Consortium Vitamin D Pooling Project of Rarer Cancers. Am J Epidemiol 2010; 172:81-93; PMID:20562185; http://dx.doi.org/10.1093/aje/kwq120.
61. Baggerly LL, Garland CF. Vitamin D and pancreatic cancer risk-no U-shaped curve. Anticancer Res 2012; 32:981-4; PMID:22399620.
62. Stolzenberg-Solomon RZ, Hayes RB, Horst RL, Anderson KE, Hollis BW, Silverman DT. Serum vitamin D and risk of pancreatic cancer in the prostate, lung, colorectal, and ovarian screening trial. Cancer Res 2009; 69:1439-47; PMID: 19208842; http://dx.doi.org/10.1158/0008-5472.CAN-08-2694.
63. Wolpin BM, Ng K, Bao Y, Kraft P, Stampfer MJ, Michaud DS, et al. Plasma 25-hydroxyvitamin D and risk of pancreatic cancer. Cancer Epidemiol Biomarkers Prev 2012; 21:82-91; PMID:22086883; http://dx.doi.org/10.1158/1055-9965.EPI-11-0836.
64. Falleti E, Bitetto D, Fabris C, Cussigh A, Fontanini E, Fomasiere E, et al. Vitamin D receptor gene polymorphisms and hepatocellular carcinoma in alcoholic cirrhosis. World J Gastroenterol 2010; 16:3016-24; PMID:20572305; http://dx.doi.org/10.3748/wjg.vl6.i24.3016.
65. Mondul AM, Weinstein SJ, Männistö S, Snyder K, Horst RL, Virtamo J, eta!. Serum vitamin D and risk of bladder cancer. Cancer Res 2010; 70:9218-23; PMID:20978193; http:/ldx.doi.org/10.1158/0008-5472.CAN-10-0985.
66. Mondul AM, Weinstein SJ, Horst RL, Purdue M, Albanes D. Serum vitamin D and risk of bladder cancer in the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening trial. Cancer Epidemiol Biomarkers Prev 2012; 21: 1222-5; PMID:22623707; http://dx.doi.org/10.1158/1055-9965.EPI-12-0439.
67. McCullough ML, Bandera EV, Moore OF, Kushi LH. Vitamin D and calcium intake in relation to risk of endometrial cancer: a systematic review of the literature. Prev Med 2008; 46:298-302; PMID: 18155758; http://dx.doi.org/10.1016/j.ypmed.2007.11.010.
68. Zeleniuch-Jacquotte A, Gallicchio L, Hartmuller V, Helzlsouer KJ, Mc Cullough ML, Setiawan VW, et al. Circulating 25-hydroxyvitamin D and risk of endometrial cancer: Cohort Consortium Vitamin D Pooling Project of Rarer Cancers. Am J Epidemiol 2010; 172:36-46; PMID:20562189; http://dx.doi.org/10.1093/aje/kwq114.
69. Yin L, Grandi N, Raum E, Haug U, Arndt V, Brenner H. Meta-analysis: Circulatingvitamin D and ovarian cancer risk. Gynecol Oncol 2011; 121:369-75; PMID:21324518; http://dx.doi.org/10.1016/j.ygyno.2011.01.023.
70. Zheng W, Danforth KN, Tworoger SS, Goodman MT, Arslan AA, Patel AV, et al. Circulating25-hydroxyvitamin D and risk of epithelial ovarian cancer: Cohort Consortium Vitamin D Pooling Project of Rarer Cancers. Am J Epidemiol 2010; 172:70-80; PMID:20562186; http://dx.doi.org/10.1093/aje/kwql18.
71. Oreli-Kotikangas H, Schwab U, Osterlund P, Saarilahti K, Mäkitie O, Mäkitie AA. High prevalence of vitamin D insufficiency in patients with head and neck cancer at diagnosis. Head Neck 2012; 34:1450-5; PMID:22287291; http://dx.doi.org/10.1002/hed.21954.
72. Arem H, Weinstein SJ, Horst RL, Virtamo J, Yu K, Albanes D, et al. Serum 25-hydroxyvitamin D and risk of oropharynx and larynx cancers in Finnish men. Cancer Epidemiol Biomarkers Prev 2011; 20: 1178-84; PMID:21527582; http://dx.doi.org/10.1158/1055-9965.EPI-11-0 153.
73. Gallicchio L, Moore LE, Stevens VL, Ahn J, Albanes D, Hartmuller V, eta!. Circulating 25-hydroxyvitamin D and risk ofkidney cancer: Cohort Consortium Vitamin D Pooling Project of Rarer Cancers. Am J Epidemiol 2010; 172:47-57; PMID:20562187; http://dx.doi.org/10.1093/aje/kwq115.
74. Purdue MP, Freedman OM, Gapstur SM, Helzlsouer KJ, Laden F, Lim U, et al. Circulating25-hydroxyvitamin D and risk of non-hodgkin lymphoma: Cohort Consortium Vitamin D Pooling Project of Rarer Cancers. Am J Epidemiol 2010; 172:58-69; PMID:20562184; http://dx.doi.org/10.1093/aje/kwq117.
75. Lim U, Freedman DM, Hollis BW, Horst RL, Purdue MP, Chatterjee N, et al. A prospective investigation of serum25-hydroxyvitamin Dandriskoflymphoidcancers. Int JCancer 2009; 124:979-86;PMID:l9035445; http://dx.doi.org/10.1002/ijc.23984.
76. Mohr SB, Gorham ED, Garland CF, Grant WB, Garland FC. Low ultraviolet Band increased risk of brain cancer: an ecological study ofl75 countries. Neuroepidemiology 2010; 35:281-90; PMID:20948235; http://dx.doi.org/10.1159/000314350.
77. Roskies M, Dolev Y, Caglar D, Hier MP, Mlynarek A, Majdan A, et al. Vitamin D deficiency as a potentially modifiable risk factor for thyroid cancer. J Otolaryngol Head Neck Surg 2012; 41: 160-3; PMID:22762696.
78. Grant WB. Effect of follow-up time on the relation between prediagnostic serum 25-hydroxyvitamin D and all-cause mortality rate. Dermatoendocrinol 2012; 4:198-202; PMID:22928077; http://dx.doi.org/10.4161/derm.20514.
79. Wang Y, Jacobs EJ, Mc Cullough ML, Rodriguez C, Thun MJ, Calle EE, et al. Comparing methods for accounting for seasonal variability in a biomarker when only a single sample is available: insights from simulations based on serum 25-hydroxyvitamin d. Am J Epidemiol 2009; 170:88-94; PMID: 19406919; http://dx.doi.org/10.1093/aje/kwp086.
80. Roth HJ, Schmidt-Gayk H, Weber H, Niederau C. Accuracy and clinical implications ofseven25-hydroxyvitamin D methods compared with liquid chromatography-tandem mass spectrometry as a reference. Ann Clin Biochem 2008; 45: 153-9; PMID:18325178; http://dx.doi.org/10.1258/acb.2007.00709l.
81. Moon HW, Cho JH, Hur M, Song J, Oh GY, Park CM, et al. Comparison of four current 25-hydroxyvitamin D assays. Clin Biochem 2012; 45:326-30;PMID:22244986;http://dx.doi.org/10.1016/j.clinbiochem.2011.12.025.
82. Perna L, Haug U, Schöttker B, Müller H, Raum E, Jansen EH, et al. Public health implications of standardized 25-hydroxyvitamin D levels: a decrease in the prevalence of vitamin D deficiency among older women in Germany. Prev Med 2012; 55:228-32; PMID:22743294; http://dx.doi.org/10.1016/j.ypmed.2012.06.010.
83. Bertrand KA, Giovannucci E, Liu Y, Malspeis S, Eliassen AH, Wu K, et al. Determinants of plasma 25-hydroxyvitamin D and development of prediction models in three US cohorts. [Epub ahead of print]. Br J Nutr 2012; 108:1889-96; PMID:22264926; http://dx.doi.org/10.1017/S0007114511007409.